Reata is committed to developing novel therapeutics for patients with serious and life-threatening diseases. Reata’s lead candidates, bardoxolone methyl and omaveloxolone, are being evaluated in pivotal clinical trials for the treatment of a variety of chronic and genetic diseases for which a substantial unmet need exists. These include: Alport syndrome (AS), Friedreich’s ataxia (FA), connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), and autosomal dominant polycystic kidney disease–chronic diseases (ADPKD) in which mitochondrial dysfunction and inflammation are implicated. Reata is also evaluating bardoxolone methyl for other rare forms of CKD, including: IgA nephropathy, type 1 diabetic CKD, and focal segmental glomerulosclerosis.

Click on the video below to better understand the disease manifestations from a patient’s perspective.

Learn More About
Friedreich’s ataxia

Click on the video below to better understand the disease manifestations from a patient’s perspective.

Learn More About
Alport syndrome